Campbell & CO Investment Adviser LLC Purchases New Stake in Fluidigm Co. (FLDM)

Campbell & CO Investment Adviser LLC bought a new position in shares of Fluidigm Co. (NASDAQ:FLDM) during the third quarter, HoldingsChannel.com reports. The firm bought 15,600 shares of the medical research company’s stock, valued at approximately $117,000.

A number of other hedge funds have also recently added to or reduced their stakes in FLDM. LMR Partners LLP acquired a new stake in Fluidigm during the second quarter worth about $144,000. Wells Fargo & Company MN grew its position in Fluidigm by 64.8% during the first quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock worth $169,000 after buying an additional 11,377 shares in the last quarter. Fairpointe Capital LLC acquired a new stake in Fluidigm during the second quarter worth about $238,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Fluidigm during the second quarter worth about $240,000. Finally, Paloma Partners Management Co grew its position in Fluidigm by 234.7% during the second quarter. Paloma Partners Management Co now owns 56,900 shares of the medical research company’s stock worth $339,000 after buying an additional 39,900 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on FLDM. Zacks Investment Research raised Fluidigm from a “sell” rating to a “hold” rating in a research report on Thursday, September 20th. BidaskClub downgraded Fluidigm from a “buy” rating to a “hold” rating in a research report on Friday, September 28th. Finally, Piper Jaffray Companies raised Fluidigm from a “neutral” rating to an “overweight” rating in a research report on Friday, November 2nd.

FLDM stock opened at $8.26 on Friday. Fluidigm Co. has a twelve month low of $4.65 and a twelve month high of $8.69. The stock has a market cap of $325.59 million, a P/E ratio of -6.94 and a beta of 2.84. The company has a debt-to-equity ratio of 7.56, a quick ratio of 1.45 and a current ratio of 1.85.

Fluidigm (NASDAQ:FLDM) last released its earnings results on Thursday, November 1st. The medical research company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.20). Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. The firm had revenue of $28.96 million for the quarter, compared to analyst estimates of $27.50 million. On average, sell-side analysts predict that Fluidigm Co. will post -0.99 earnings per share for the current fiscal year.

In other news, insider Levin Capital Strategies, L.P. bought 47,768 shares of the firm’s stock in a transaction that occurred on Wednesday, November 14th. The shares were acquired at an average cost of $7.55 per share, with a total value of $360,648.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have purchased 122,180 shares of company stock worth $910,163. 2.20% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Campbell & CO Investment Adviser LLC Purchases New Stake in Fluidigm Co. (FLDM)” was reported by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.wkrb13.com/2018/11/24/campbell-co-investment-adviser-llc-purchases-new-stake-in-fluidigm-co-fldm.html.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

See Also: What are earnings reports?

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply